The approval of new CFTR modulators has brought about a radical change in the treatment of CF patients.6 In particular, the available experience with the triple therapy consisting of Elexacaftor, Tezacaftor, and Ivacaftor shows encouraging results in terms of improvement in several aspects of the disease compared to other modulators.9 This evidence concerns the gene CFTR and cystic fibrosis.